124 related articles for article (PubMed ID: 36811410)
1. Vertical level of blood cell division cycle 42 predicts response and survival benefits to PD-1 inhibitor-based regimen in metastatic colorectal cancer patients.
Jiang L; Shen Y; Wang Y
Scand J Clin Lab Invest; 2023 Apr; 83(2):103-110. PubMed ID: 36811410
[TBL] [Abstract][Full Text] [Related]
2. Serum Cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with Tumor Features, Clinical Response, and Survival.
Zhang L; Zhang S; Han Z; Liu Z; Xu Y; Li X; Miao G; Niu L
Tohoku J Exp Med; 2024 Mar; 262(2):133-141. PubMed ID: 37914283
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of circulating CDC42 and its correlation with demographic characteristics, comorbidities, tumor features, chemotherapeutic regimen and survival profile in non-small-cell lung cancer patients.
Yan J; Wan D
J Clin Lab Anal; 2022 Feb; 36(2):e24140. PubMed ID: 34952984
[TBL] [Abstract][Full Text] [Related]
4. The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients.
Gao S; Xue J; Wu X; Zhong T; Zhang Y; Li S
J Clin Lab Anal; 2022 Jul; 36(7):e24572. PubMed ID: 35735582
[TBL] [Abstract][Full Text] [Related]
5. Serum cell division cycle 42 reflects the treatment response and survival in patients with advanced cervical cancer who receive immune checkpoint inhibitor treatment.
Guo L; Su Y; Liu X; Xie W; Meng S; Liu Y; Wang W; Lv X; Wang C
Oncol Lett; 2023 Sep; 26(3):414. PubMed ID: 37600330
[TBL] [Abstract][Full Text] [Related]
6. Early low blood MALT1 expression levels forecast better efficacy of PD‑1 inhibitor‑based treatment in patients with metastatic colorectal cancer.
Li C; Yu F; Xu W
Oncol Lett; 2023 Aug; 26(2):329. PubMed ID: 37415633
[TBL] [Abstract][Full Text] [Related]
7. Serum cell division control 42 reflects treatment response and survival profiles in recurrent or metastatic oral squamous cell carcinoma patients who receive programmed death-1 inhibitors.
Chen Y; Chen Y; Liu W
Int Immunopharmacol; 2024 Mar; 129():111547. PubMed ID: 38290205
[TBL] [Abstract][Full Text] [Related]
8. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
Front Immunol; 2022; 13():809971. PubMed ID: 35185898
[TBL] [Abstract][Full Text] [Related]
9. Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes.
Xu J; Shao R; Zhang X; Yao D; Han S
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102149. PubMed ID: 37247692
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal change of circulating tumor cell level and its relationship with immune checkpoint inhibitor-based treatment benefits in unresectable, metastatic colorectal cancer patients.
Fan H; Bai L; Bai K
Scand J Clin Lab Invest; 2023 Jul; 83(4):227-233. PubMed ID: 37247200
[TBL] [Abstract][Full Text] [Related]
11. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
Li C; Yu F; Xu W
J Clin Pharm Ther; 2022 Dec; 47(12):2325-2334. PubMed ID: 36495117
[TBL] [Abstract][Full Text] [Related]
13. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
14. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
Zhang Q; Jin D; Mou X; Ye H
J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
[TBL] [Abstract][Full Text] [Related]
15. Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
Formica V; Cereda V; di Bari MG; Grenga I; Tesauro M; Raffaele P; Ferroni P; Guadagni F; Roselli M
Med Oncol; 2013 Dec; 30(4):743. PubMed ID: 24114613
[TBL] [Abstract][Full Text] [Related]
16. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
20. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
[Next] [New Search]
